Table of Contents Author Guidelines Submit a Manuscript
Journal of Toxicology
Volume 2012 (2012), Article ID 308594, 7 pages
http://dx.doi.org/10.1155/2012/308594
Research Article

Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies

1Biologics Research, Janssen Research and Development, LLC, 145 King of Prussia Road, Radnor, PA 19087, USA
2Safety Assessment, AstraZeneca Pharmaceuticals, Pepparedsleden 1, 431 83 Mölndal, Sweden
3Haskell Global Centers for Health and Environmental Sciences, DuPont Central Research and Development, Newark, DE 19711, USA
4Safety Assessment, AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Waltham, MA 02451, USA

Received 15 March 2012; Accepted 10 April 2012

Academic Editor: J. J. Stegeman

Copyright © 2012 Linda R. Barone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Lullmann-Rauch, “Drug-induced lysosomal storage disorders,” in Lysosomes in Applied Biology and Thereapeutics, J. T. Dingle, P. J. Jacques, and I. H. Shaw, Eds., pp. 49–128, North-Holland Publishing, Amsterdam, The Netherlands, 1979. View at Google Scholar
  2. M. J. Reasor, K. L. Hastings, and R. G. Ulrich, “Drug-induced phospholipidosis: issues and future directions,” Expert Opinion on Drug Safety, vol. 5, no. 4, pp. 567–583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. U. P. Kodavanti and H. M. Mehendale, “Cationic amphilic drugs and phospholipid storage disorder,” Pharmacological Reviews, vol. 42, no. 4, pp. 327–354, 2001. View at Google Scholar · View at Scopus
  4. W. A. Daniel and J. Wójcikowski, “The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions,” Toxicology and Applied Pharmacology, vol. 158, no. 2, pp. 115–124, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. A. D. Wladyslawa, J. Wójcikowski, and A. Palucha, “Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping,” British Journal of Pharmacology, vol. 134, no. 4, pp. 807–814, 2001. View at Google Scholar · View at Scopus
  6. J. J. Shacka, B. J. Klocke, M. Shibata et al., “Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons,” Molecular Pharmacology, vol. 69, no. 4, pp. 1125–1136, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Anderson and J. Borlak, “Drug-induced phospholipidosis,” FEBS Letters, vol. 580, no. 23, pp. 5533–5540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Reasor and S. Kacew, “Drug-induced phospholipidosis: are there functional consequences?” Experimental Biology and Medicine, vol. 226, no. 9, pp. 825–830, 2001. View at Google Scholar · View at Scopus
  9. M. E. Cartwright, J. Petruska, J. Arezzo et al., “Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects,” Toxicologic Pathology, vol. 37, no. 7, pp. 902–910, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. J. Gonzalez-Rothi, D. S. Zander, and P. R. Ros, “Fluoxetine hydrochloride (Prozac)-induced pulmonary disease,” Chest, vol. 107, no. 6, pp. 1763–1765, 1995. View at Google Scholar · View at Scopus
  11. D. Laplane and M. G. Bousser, “Polyneuropathy during perhexiline maleate therapy,” International Journal of Neurology, vol. 15, no. 3-4, pp. 293–300, 1981. View at Google Scholar · View at Scopus
  12. M. Mäntyjärvi, K. Tuppurainen, and K. Ikäheimo, “Ocular side effects of amiodarone,” Survey of Ophthalmology, vol. 42, no. 4, pp. 360–366, 1998. View at Google Scholar
  13. M. P. Mingeot-Leclercq and P. M. Tulkens, “Aminoglycosides: nephrotoxicity,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1003–1012, 1999. View at Google Scholar · View at Scopus
  14. S. L. Vonderfecht, M. L. Stone, R. R. Eversole et al., “Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence,” Toxicologic Pathology, vol. 32, no. 3, pp. 318–325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. E. A. Tengstrand, G. T. Miwa, and F. Y. Hsieh, “Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities,” Expert Opinion on Drug Metabolism and Toxicology, vol. 6, no. 5, pp. 555–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. K. Morelli, M. Buehrle, F. Pognan, L. R. Barone, W. Fieles, and P. J. Ciaccio, “Validation of an in vitro screen for phospholipidosis using a high-content biology platform,” Cell Biology and Toxicology, vol. 22, no. 1, pp. 15–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. H. T. Yudate, T. Kai, M. Aoki et al., “Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24-hours after single dose administration,” Toxicology, vol. 295, no. 1–3, pp. 1–7, 2012. View at Google Scholar
  18. F. Lombardo, R. S. Obach, M. Y. Shalaeva, and F. Gao, “Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data,” Journal of Medicinal Chemistry, vol. 45, no. 13, pp. 2867–2876, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. U. M. Hanumegowda, G. Wenke, A. Regueiro-Ren, R. Yordanova, J. P. Corradi, and S. P. Adams, “Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds,” Chemical Research in Toxicology, vol. 23, no. 4, pp. 749–755, 2010. View at Publisher · View at Google Scholar · View at Scopus